title: Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
abstract: The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma. Treatment consisted of an intravenous bolus injection of doxorubicin at a dose of 50 mg/m2 followed by a 24-h infusion of ifosfamide at 5 g/m2 plus mesna, with therapy being repeated every 3 weeks until disease progression or unacceptable toxicity occurred. Of the 203 patients entered, 175 were evaluable for response. The overall response rate was 35% (95% confidence interval, 28%-42%), with 9% of patients achieving complete responses and 26% showing partial responses. The median time to progression was 29 weeks for all evaluable patients and 67, 40, and 28 weeks for complete and partial responders and patients with stable disease, respectively. The median duration of survival was 58 weeks. Myelosuppression was the dose-limiting toxicity, resulting in leukopenia (World Health Organization grades 3 and 4) in 73% of the evaluable patients. Other side effects were rare and usually well manageable.
authors.affiliation: Universitätsklinik Essen, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Schütte
authors.forename: H T
authors.initials: HT
authors.lastname: Mouridsen
authors.forename: W
authors.initials: W
authors.lastname: Steward
authors.forename: A
authors.initials: A
authors.lastname: Santoro
authors.forename: A T
authors.initials: AT
authors.lastname: van Oosterom
authors.forename: R
authors.initials: R
authors.lastname: Somers
authors.forename: G
authors.initials: G
authors.lastname: Blackledge
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: P
authors.initials: P
authors.lastname: Dombernowsky
authors.forename: D
authors.initials: D
authors.lastname: Thomas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D007069:Ifosfamide